Esperion Therapeutics | ESPR - Beneficio Bruto En Ventas

Precio De Mercado
2.59
Cambio Diario
0.04 1.37%
Mensual
-21.67%
Anual
48.56%
Q1 Expectativa
2.47




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 23.17M 961K 2025-12
Amgen USD 6.48B 307M 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Cipla INR 41.64B 6.31B 2025-12
CSL USD 4.46B 2.71B 2025-12
Cytokinetics USD 17.76M 15.82M 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Geron USD 46.71M 525K 2025-12
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Merck USD 13.42B 431M 2025-09
Minerva Neurosciences -4.27M 26.79M 2024-12
Moderna USD 226M 583M 2025-12
Nektar Therapeutics USD 13.75M 650K 2024-06
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12